Defibrotide in COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

April 7, 2021

Study Completion Date

May 28, 2021

Conditions
Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure
Interventions
DRUG

Defibrotide Injection

Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days

Trial Locations (1)

20132

Ospedale San Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT04335201 - Defibrotide in COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter